{"name":"HTA Co., Ltd.","slug":"hta-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Florastamin[18F] Injection","genericName":"Florastamin[18F] Injection","slug":"florastamin-18f-injection","indication":"Detection and localization of bacterial infections","status":"phase_3"},{"name":"Technetium[99mTc] Methylenediphosphonate Injection","genericName":"Technetium[99mTc] Methylenediphosphonate Injection","slug":"technetium-99mtc-methylenediphosphonate-injection","indication":"Skeletal scintigraphy for detection of bone metastases","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Sodium Fluoride F-18 Injection","genericName":"Sodium Fluoride F-18 Injection","slug":"sodium-fluoride-f-18-injection","indication":"Detection and monitoring of bone metastases","status":"phase_3"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"[18F]Florastamin Injection","genericName":"[18F]Florastamin Injection","slug":"18f-florastamin-injection","indication":"Hypercholesterolemia","status":"phase_3"}]}],"pipeline":[{"name":"Florastamin[18F] Injection","genericName":"Florastamin[18F] Injection","slug":"florastamin-18f-injection","phase":"phase_3","mechanism":"Florastamin[18F] is a fluorine-18 labeled radiopharmaceutical that targets bacterial infection and inflammation for positron emission tomography (PET) imaging.","indications":["Detection and localization of bacterial infections","Imaging of inflammatory lesions"],"catalyst":""},{"name":"Sodium Fluoride F-18 Injection","genericName":"Sodium Fluoride F-18 Injection","slug":"sodium-fluoride-f-18-injection","phase":"phase_3","mechanism":"Sodium Fluoride F-18 Injection is a radiopharmaceutical used for diagnostic imaging.","indications":["Detection and monitoring of bone metastases","Assessment of bone health in patients with cancer"],"catalyst":""},{"name":"Technetium[99mTc] Methylenediphosphonate Injection","genericName":"Technetium[99mTc] Methylenediphosphonate Injection","slug":"technetium-99mtc-methylenediphosphonate-injection","phase":"phase_3","mechanism":"Technetium-99m methylenediphosphonate is a radiopharmaceutical that binds to bone mineral and is used for skeletal scintigraphy to detect areas of altered bone metabolism.","indications":["Skeletal scintigraphy for detection of bone metastases","Evaluation of bone infections (osteomyelitis)","Assessment of fractures and stress injuries","Evaluation of metabolic bone disease"],"catalyst":""},{"name":"[18F]Florastamin Injection","genericName":"[18F]Florastamin Injection","slug":"18f-florastamin-injection","phase":"phase_3","mechanism":"Florastatin is a radiolabeled version of florastatine, a statin used to lower cholesterol levels.","indications":["Hypercholesterolemia"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxQZjM3dW9BM2QyS1FyaVQ2anA0RVA4ZWNDdDJBQV9PekxYWFFFanNWNXJoYWxWRktIQ1EzaHdxRkU1TG4zRjhzWjI1YzhmdGg2cVp0cmRVN3hHUS0xTVlaYkVkWTdCLS0yaFIwR2FoVHY3dl9KaUViSnFsNWNwVzZsMmZ5WWVFRW9XZkFaOXlsYmp0c3hXVEt6LXhXTGpIOHJTd01IUVB0eENHMnMySHdScC1zV18?oc=5","date":"2025-10-07","type":"pipeline","source":"Lexology","summary":"What hidden legal risks do pharma companies face with the EU's new HTA requirements? - Lexology","headline":"What hidden legal risks do pharma companies face with the EU's new HTA requirements?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxOcWdjdFZiUkkzbjYxdmhidmFUN25tNXdiNTgxNjV4NGphUjBYNmRlWG8tLVJxMXdqLWwtUllOTkJOWHRoaFhWZ1Vuc0Jqbmt2ZjBpNWMzdlBzV2FycERIeHlVcWFaX2ZtRE1JWnFDSzRMeEoyYVBib1pkRzVvRlZmazdpaU1QMzJaQ1FiMWJrRllueGhyQmFwRlFyUlJ2US1RZ0phVldtSTdCYmdwMmotWVFXY0pxcHFfQXc?oc=5","date":"2025-08-26","type":"pipeline","source":"pharmaphorum","summary":"Early strategic evidence planning is a key success factor in the EU HTA landscape: Pamela Vo on navigating the JCA era - pharmaphorum","headline":"Early strategic evidence planning is a key success factor in the EU HTA landscape: Pamela Vo on navigating the JCA era","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxQdTBYSG9GSjNySUZfWjNuVmVUUm1ybHVzQi1tOE1ZcVlpWFlOLV9kcVhkSWNzVHhZcWpwbF8xc3RzRzVMdmMyY3VmM1BZMlhTN3FiLUlKdjlhSVIzQXBtN2JpMjNPSWxtdDBkYnd3RTNPS2FYOUI5SmRXNXJDWDF4bWtScVlieDYzOHlfWVZVUU9ZNE12WWZkSlVWMloyRUV4OTFjc1pHUkYzZEliSWc?oc=5","date":"2024-11-19","type":"pipeline","source":"PMLiVE","summary":"EU Joint Clinical Assessment (JCA) – Implications for Pharma and Medtech - PMLiVE","headline":"EU Joint Clinical Assessment (JCA) – Implications for Pharma and Medtech","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxNcy1SX2ZzbU5fTFRUZzY0TUl6ajVmVHpaMVNWMTZwY1V2WEVMcVNhaDRhdDgyY2RNejJkWjZZMl9oYll2MFgxWE9Sd3FkSmlBT01hLUZWTG1PQURscFVpRG94M3RpYXBOUWFhYmZ3RzQ3OHlLc2RwdGgzekVqM3pYbTN2bkp6eGtTZ21TZloxU0V2YWs?oc=5","date":"2024-07-19","type":"pipeline","source":"PwC","summary":"Turning EU HTA regulation into a strategic opportunity - PwC","headline":"Turning EU HTA regulation into a strategic opportunity","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE1WN3hBRmg1WUp2bWRhZHhXQ2Zyc19KRXAxLWxtak96Q1BkaVJtenh3clI2WkwyaURVQXBLQXFBYURLcHBIUVNVaTFTTm5OMl9sLXVSb1RtY3JzbS0wc3RZWENzUEVrdDlONEhZVHBUWmRMTGlSWnBFWFRQSEM?oc=5","date":"2024-05-01","type":"pipeline","source":"jnm.snmjournals.org","summary":"Landscape of Nuclear Medicine in China and Its Progress on Theranostics - jnm.snmjournals.org","headline":"Landscape of Nuclear Medicine in China and Its Progress on Theranostics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxNNUxRV29Qb1BEZzdFWlpkblNOVkZka2tTWE56UmktNlVSblFOcGtlQURHX3VqcS1qV0c1UndzOWdUTHhaTlFVX2owUFkxQXVWZllCVlBTbVR2QzBDTEJPTk1WUFVWa25HV2dWY3ZyR0JhLUJINlVWTjJrVXVfN2k1b3lwdFd3UQ?oc=5","date":"2024-04-02","type":"pipeline","source":"PharmTech.com","summary":"Looking at the Potential Impact of JCA on Pharma - PharmTech.com","headline":"Looking at the Potential Impact of JCA on Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxNYzZrUGppOTl2RnAxdm1GMTJnZzNURk1OeGEwZXc5MTZYQll5RWJiZWFiX2FPWFRka1RNYldOanB5aHZ2alhYZlZwQkdMd0liaWNzMEhia3Vtd21KZ1pDV3pvTkhERmY4b2Z0WElMZzJKSXVuemdXY0dXQzFqcWRSQ09VbHZEeHd3VXBqTmpza0x1a1JPVlFxcEVudXBSaUFiQUp6RW1VVlFiXzJ3d2pDMmN3?oc=5","date":"2023-07-03","type":"pipeline","source":"BioWorld News","summary":"Sinotau nets $152M in financing to develop radiopharmaceuticals in China - BioWorld News","headline":"Sinotau nets $152M in financing to develop radiopharmaceuticals in China","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE1UNVplTngwYVRDNGdldHM1OVR3OWNDSVlZMVI3ZW9DaEhvQVczN3VMOHFscFhvY040Z2NKcENUVFRNUnBWZVQtdHc4bkhldXM3WHRmSG5KYWkwM3NLUmpXVW5sUFZjTE9FNGhyMzhB?oc=5","date":"2023-03-17","type":"regulatory","source":"KED Global","summary":"S.Korea's FutureChem gets approval for phase 3 clinical trials in China - KED Global","headline":"S.Korea's FutureChem gets approval for phase 3 clinical trials in China","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxNZEJ1UkV0TGJuOTZ3WGU0TEtJQkpaRUpydTN6STEwRW96bmtZZ1Z4c2JQVkt5RE9rOWxwNTRfaG5uR1htRW5tVlBaM0FFOUJySWFpcWlrMHU3MUdMbWhacnJ5ekFKam1TbHdfMVZSdFpZV2JBMUtOVjhvVnJ0dGxuZkV1Q2NKLV9SNHRiSVU1X2pjMUU?oc=5","date":"2022-07-17","type":"pipeline","source":"Frontiers","summary":"Challenges and Opportunities for Companies to Build HTA/Payer Perspectives Into Drug Development Through the Use of a Dynamic Target Product Profile - Frontiers","headline":"Challenges and Opportunities for Companies to Build HTA/Payer Perspectives Into Drug Development Through the Use of a Dy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxPdThpczNTRDZtSXd5R01JWUhRR2RfdEZzSUlTcDdQN1o1b1NDZkgtLTlQUnFFbmJxY1duSExiYXN4SE0tQk95OHgzamQwTW1NSGt0cjJsS0RLa1VYMU1QOTNZcWxmUUhENHdkS25wdG0wRVA3VTRNWmhoTlgtSlFXMDk2dEE0YjhWeGd0T3lCLUZ2V2xzVE5JYkUwc1lQZw?oc=5","date":"2021-05-26","type":"pipeline","source":"Pf Media","summary":"Access Matters: The rise of the payer and implications for pharma - Pf Media","headline":"Access Matters: The rise of the payer and implications for pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxNem1SMHgxYkxybDJNcEhiN3pGUkNrTm4tNHRaSzZhcHBibGlFZDB0WU5VMXExU1pQUTBYeEJJY1BVSjljNThwb3V3T0NmeXU2YjRtcEFTMFdCd2V2ZWFhWXhVR3ExWGRvT1FUaG4zb05NQnlQRjJLM2I2QUFHZ1o5d0lTd2x5bHFmT05Gak1EWjQxVnZsUW4yYmc4am9OdG80V284enpCa2NJRVlhTWtjWm1uQzZucEFC?oc=5","date":"2020-10-15","type":"pipeline","source":"BioSpectrum Asia","summary":"Chris Hourigan steps in as Company Group Chairman for Janssen APAC - BioSpectrum Asia","headline":"Chris Hourigan steps in as Company Group Chairman for Janssen APAC","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxNTEZHTUpFaXFjQUI0Y0NsRWtXTzFYUkpGT0toeXR6NWZfWEtUTXBCZHVzNzM1VnZadjBUSmlwMkowaDhRWW1YQUxCYWdGMUhxUTdSNmdOTmNIN3dzSVM0Zm5Pd2ZsMmRlN3JqSlJaM3FreWx4aU95X09lODQwd1UyNHF2OXdvT1kybGU5SHRwSVhEaEkxODBJOEg2dw?oc=5","date":"2017-12-15","type":"pipeline","source":"MIT News","summary":"Pioneering a health care innovation ecosystem to better serve patients - MIT News","headline":"Pioneering a health care innovation ecosystem to better serve patients","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"phase_3":4},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}